What Should Be the Definition of “Remission” in Pulmonary Arterial Hypertension?
Right Heart Journal · 2026
DOI: 10.65721/rhj.2026.1.e11 ↗Kurz gefasst
Fachartikel in der Zeitschrift Right Heart Journal, 2026. Verfasst von Ayane Miyagi und 3 weiteren Autor:innen. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
The recent advent of sotatercept, a novel agent targeting the activin signaling pathway, has significantly improved the treatment of pulmonary arterial hypertension (PAH), with the potential to modify the underlying disease process rather than merely provide symptomatic relief.This paradigm shift has reinvigorated discussions on new therapeutic goalsparticularly the possibility of achieving PAH remission.In oncology and chronic inflammatory diseases, remission is a well-established concept, defined either by the complete disappearance of disease in malignant conditions or by the sustained absence of clinical activity in non-malignant disorders.In contrast, applying the concept of remission to PAH remains challenging, as direct assessment of pulmonary vascular remodeling is not currently feasible in clinical practice.Therefore, the definition of remission must rely on
Zitieren
APA
Miyagi, A., Kuronuma, K., Shimokawahara, H., & Matsubara, H. (2026). What Should Be the Definition of “Remission” in Pulmonary Arterial Hypertension?. Right Heart Journal. https://doi.org/10.65721/rhj.2026.1.e11
Vancouver
Miyagi A, Kuronuma K, Shimokawahara H, Matsubara H. What Should Be the Definition of “Remission” in Pulmonary Arterial Hypertension?. Right Heart Journal. 2026. doi:10.65721/rhj.2026.1.e11
BibTeX
@article{Miyagi2026,
author = {Miyagi, Ayane and Kuronuma, Keiichiro and Shimokawahara, Hiroto and Matsubara, Hiromi},
title = {What Should Be the Definition of “Remission” in Pulmonary Arterial Hypertension?},
journal = {Right Heart Journal},
year = {2026},
doi = {10.65721/rhj.2026.1.e11}
}
EUVIMED